This episode examines the pharmacologic basis of GLP-1 adverse reactions, dose titration strategies, and patient-specific factors shaping therapy safety.
Judith Hey-Hadavi
Advertisement
Dr. Juliana (Judith) Hey-Hadavi is an internationally recognized physician-executive with over 20 years of leadership experience in global medical affairs, clinical innovation, and drug development (Phases I-IV). Board-certified in Internal Medicine and Endocrinology, she brings a distinct perspective of scientific rigor, operational excellence, and visionary leadership to the advancement of therapies across diverse therapeutic areas. Her expertise spans CVMET (incl. obesity, diabetes, MASH, dyslipidemia, growth disorders, acromegaly), Neurology (stroke, Alzheimer’s disease), Immunology & Inflammation (rheumatoid arthritis, lupus, aplastic anemia, asthma), and Hospital Sterile Injectables.
Articles by Judith Hey-Hadavi
In the second episode of our GLP-1 Therapy Insights series, experts Judith Hey-Hadavi from Worldwide Clinical Trials and Nicole Snow from Olympia Pharmaceuticals discuss the evolution of GLP-1 receptor agonists from protein-based therapies to small-molecule options.
Explore GLP-1 receptor agonists with experts Judith Heij-Hadavi and Nicole Snow: molecular design, patient care, oral therapies, and analytical insights.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on LCGC International
1
Navigating Adverse Reactions in GLP-1 Treatment
2
Decoding Sweet Potato Drought Resilience: Metabolomic Evidence from UPLC-MS Profiling
3
Toward Safer Diabetes Devices: GC–MS Detection of Allergens in Sensors, Pumps, and Infusion Sets
4
Shifting GLP-1 Receptor Agonists from Proteins to Small Molecules
5
